Cargando…
Giving anti-VEGF injections: an update from Burundi
Autor principal: | Niyonzima, Jean Claude |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Centre for Eye Health
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436764/ https://www.ncbi.nlm.nih.gov/pubmed/37600680 |
Ejemplares similares
-
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey
por: Sheth, Jay U, et al.
Publicado: (2021) -
Effect of Decorin and Bevacizumab on oxygen-induced retinopathy in rat models: A comparative study
por: Duran Güler, Seda, et al.
Publicado: (2021) -
Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab
por: Verma, Lalit, et al.
Publicado: (2021) -
One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders
por: Salimi, Ali, et al.
Publicado: (2021) -
Anti-inflammatory Property of AMP-activated Protein Kinase
por: Noor, Humaira B., et al.
Publicado: (2020)